Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1634 1682
This examiner grants 53% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18329972 | THERAPEUTIC AND DIAGNOSTIC METHODS FOR IL-33-MEDIATED DISORDERS | Non-Final OA | Genentech, Inc. |
| 17596821 | Diagnostics and Treatments Based Upon Molecular Characterization of Colorectal Cancer | Final Rejection | The Board of Trustees of the Leland Stanford Junior University |
| 17869856 | METAL NANOSTRUCTURE BASED ON BIOMOLECULES AND NANOPLASMONIC BIOSENSOR USING THE SAME | Non-Final OA | Korea University Research and Business Foundation |
| 17813193 | ncRNA AND USES THEREOF | Final Rejection | THE REGENTS OF THE UNIVERSITY OF MICHIGAN |
| 17301187 | BIOMARKERS FOR ASSESSING IDIOPATHIC PULMONARY FIBROSIS | Non-Final OA | University of Pittsburgh - Of the Commonwealth System of Higher Education |
| 18025365 | METHODS OF DETECTING AN INACTIVATING MUTATION OF PBRM1 IN MENINGIOMA | Non-Final OA | Foundation Medicine, Inc. |
| 17416988 | BIOMARKERS, AND USES IN TREATMENT OF VIRAL INFECTIONS, INFLAMMATIONS, OR CANCER | Final Rejection | UNIVERSITÉ DE MONTPELLIER |
| 18538995 | TISSUE-SPECIFIC METHYLATION MARKER | Final Rejection | GRAIL, LLC |
| 16864125 | FRATAXIN-SENSITIVE MARKERS FOR DETERMINING EFFECTIVENESS OF FRATAXIN REPLACEMENT THERAPY | Final Rejection | Larimar Therapeutics, Inc. |
| 16760522 | CANCER DETECTION, CLASSIFICATION, PROGNOSTICATION, THERAPY PREDICTION AND THERAPY MONITORING USING METHYLOME ANALYSIS | Final Rejection | SINAI HEALTH SYSTEM |
| 18475641 | METHOD FOR DIAGNOSING AND TREATING SUBJECTS HAVING SINGLE NUCLEOTIDE POLYMORPHISMS IN CHROMOSOME 2, 2:107,510,000-107,540,000 LOCUS | Non-Final OA | NEURIM PHARMACEUTICALS (1991) LTD. |
| 18537204 | RNA BIOMARKERS FOR HEREDITARY ANGIOEDEMA | Non-Final OA | Takeda Pharmaceutical Company Limited |
| 17237789 | QUANTITATIVE DETECTION OF MICRO-RNAS | Final Rejection | GENFIT |
| 18160366 | METHOD AND SYSTEM OF DIAGNOSING AND TREATING NEURODEGENERATIVE DISEASE AND SEIZURES | Non-Final OA | MOREHOUSE SCHOOL OF MEDICINE |
| 18351274 | PREDICTING PEPTIDE RECEPTOR RADIOTHERAPY USING A GENE EXPRESSION ASSAY | Final Rejection | Liquid Biopsy Research LLC |
| 16562861 | DIAGNOSTIC AND PROGNOSTIC LIQUID BIOPSY BIOMARKERS FOR ASTHMA | Non-Final OA | University of Sharjah |
| 18030515 | COMPOSITION FOR DIAGNOSING COLORECTAL CANCER, RECTAL CANCER OR COLORECTAL ADENOMA BY USING CPG METHYLATION CHANGE OF LINC01798 GENE, AND USE THEREOF | Non-Final OA | GENCURIX INC. |
| 18247840 | METHOD FOR DIAGNOSING STROKE UTILIZING GENE EXPRESSION SIGNATURES | Non-Final OA | Ischemia Care LLC |
| 18014053 | IMMUNE PROFILING AND METHODS OF USING SAME TO PREDICT RESPONSIVENESS TO AN IMMUNOTHERAPY AND TREAT CANCER | Non-Final OA | GoPath Laboratories LLC |
| 18004030 | METHYLATED MARKERS FOR ACCURATE DETECTION OF PRIMARY CENTRAL NERVOUS SYSTEM AND SYSTEMIC DIFFUSE LARGE B CELL LYMPHOMA | Non-Final OA | RENMIN HOSPITAL OF WUHAN UNIVERSITY |
| 18088405 | METHOD FOR SORTING COLORECTAL CANCER AND ADVANCED ADENOMA AND USE OF THE SAME | Non-Final OA | INOGENIX Inc. |
| 17290061 | Bispecific CD123 x CD3 Diabodies for the Treatment of Hematologic Malignancies | Non-Final OA | Nottingham Trent University |
| 18008100 | COMBINATION OF GENE MARKERS AND USE THEREOF | Non-Final OA | CREATIVE, BIOSCIENCES (GUANGZHOU)CO., LTD. |
| 17996267 | FMT PERFORMANCE PREDICTION TEST TO GUIDE AND OPTIMIZE THERAPEUTIC MANAGEMENT OF GVHD PATIENTS | Non-Final OA | MaaT PHARMA |
| 17773273 | METHODS OF ANALYZING A BIOLOGICAL SAMPLE | Non-Final OA | Wallac Oy |
| 16932487 | DETECTION OF SARS-COV-2 IN A PLURALITY OF BIOLOGICAL SAMPLES | Final Rejection | Johann Wolfgang Goethe-Universität Frankfurt AM Main |
| 16962867 | TARGETED INTERVENTIONS DIRECTED AT REDUCING THE LEVELS OF CIRCULATING SUCCINATE IN A SUBJECT, AND KITS AND METHOD FOR DETERMINING EFFECTIVENESS OF SAID INTERVENTIONS | Non-Final OA | UNIVERSITAT ROVIRA I VIRGILI |
| 17605889 | Systems and Methods for Targeting Dirofilaria immitis and Dirofilaria repens | Non-Final OA | Smith College |
| 16284963 | PROSTATE CANCER ASSOCIATED CIRCULATING NUCLEIC ACID BIOMARKERS | Non-Final OA | CHRONIX BIOMEDICAL |
| 17277020 | USE OF PROBES TO DETECT TOXIC ALGAE, DETECTION METHOD AND CORRESPONDING KITS | Final Rejection | MICROBIA ENVIRONNEMENT |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy